Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age36-72
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Autism Spectrum Disorders (ASD), affect approximately 1% of the general population and are characterized by impairments in social communication associated with repetitive/stereotyped behaviors. Approximately one-third of these patients display gastrointestinal (GI) symptoms, and a growing number of studies suggest abnormalities of gut microbiota in ASD. Gut microbiota and the brain interact through complex pathways. Preliminary evidence in adults with ASD suggests that modulation of the gut microbiota by probiotics and/or prebiotics and more recently by fecal microbiota transplantation could improve GI symptoms but also socio-communication deficit, with persistent improvement at year 2.

Eligibility criteria

Qualifiers

ASD diagnosis based on DSM-5 criteria

Gastrointestinal symptoms: at least a score of 5 on 1 of the 5 GSRS domains (diarrhea, abdominal pain, constipation, indigestion, reflux) for over a period of 1 year or more

Age between 36 and 72 months

Consent from all legal guardians

Disqualifiers

Severe intellectual deficit (IQ<30) or another uncontrolled comorbidity (e.g. epilepsy)

Recent change in ASD global care (cognitive behavioral therapy 6 weeks before inclusion)

Actual or past psychotropic medication

Contraindications to colon preparation (Picoprep®) and/or to Meopa)

Trial design

Treatments tested in this trial

  • FMT Protocol

Treatment groups

5 Participants
are divided into 1 treatment group

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Fondation initiative autisme

Collaborator

Fondation Erie

Collaborator

Biocodex microbiota fondation

Collaborator